{
    "clinical_study": {
        "@rank": "137763", 
        "arm_group": [
            {
                "arm_group_label": "anastrazole", 
                "arm_group_type": "Experimental", 
                "description": "women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months"
            }, 
            {
                "arm_group_label": "GnRH analog alone", 
                "arm_group_type": "Active Comparator", 
                "description": "women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will\n      be tested for the treatment of women with endometriosis recurrence compared with classical\n      GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up\n      will be the outcomes for establishing which medical treatment is the best in endometriosis\n      recurrence treatment."
        }, 
        "brief_title": "Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Endometriosis", 
        "condition_browse": {
            "mesh_term": [
                "Endometriosis", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing\n      recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor\n      plus GnRH analog may be more effective than GnRH agonist alone in the treatment of\n      endometriosis recurrence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women affected by endometriosis showing recurrence of pain symptoms, previous surgery\n             for endometriosis\n\n        Exclusion Criteria:\n\n          -  presence of other systemic diseases"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769781", 
            "org_study_id": "CR013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "anastrazole", 
                "description": "combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months", 
                "intervention_name": "anastrazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GnRH analog alone", 
                "description": "treatment for three months with GnRH analog (leuprolide acetate) alone", 
                "intervention_name": "GnRH analog alone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Deslorelin", 
                "Anastrozole", 
                "Leuprolide", 
                "Aromatase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "endometriosis recurrence", 
            "pelvic pain", 
            "aromatase inhibitor"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "quelidebercia@hotmail.com", 
                "last_name": "FABIO SCARPELLINI, MD", 
                "phone": "+39-3278779064"
            }, 
            "contact_backup": {
                "email": "marcandrea@hotmail.com", 
                "last_name": "MARCO SBRACIA, MD", 
                "phone": "+39-3479037433"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00153"
                }, 
                "name": "Cerm-Hungaria"
            }, 
            "investigator": {
                "last_name": "FABIO SCARPELLINI, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).", 
        "other_outcome": {
            "description": "endometriosis lesions regression during treatment evidenced by MRI scan", 
            "measure": "reduction of endometriosis lesions", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_official": {
            "affiliation": "CERM-HUNGARIA", 
            "last_name": "marco sbracia, md", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "time without pain symptoms due to the disease recurrence", 
            "measure": "disease free time", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769781"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre for Endocrinology and Reproductive Medicine, Italy", 
            "investigator_full_name": "Fabio Scarpellini", 
            "investigator_title": "PRINCIPAL INVESTIGATOR", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "time needed during treatment to improve pain symptoms", 
            "measure": "time of pain disappearance", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "source": "Centre for Endocrinology and Reproductive Medicine, Italy", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre for Endocrinology and Reproductive Medicine, Italy", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}